Navigation Links
3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Date:9/30/2010

MENLO PARK, Calif., Sept. 30 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer.  

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100513/LA04336LOGO)

"We are very pleased to have Merdad as the new CEO of 3-V," said David M. Mott, 3-V's Executive Chairman, who is returning to his role as Chairman of the Board.  "Merdad's extensive drug development experiences in different therapeutic areas, including infectious disease, coupled with his experience in respiratory medicine, make him an excellent choice to lead the team."

Prior to joining 3-V Biosciences, Dr. Parsey held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as Senior Group Medical Director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas.  Prior to his tenure with Genentech, Dr. Parsey worked at Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in Respiratory, Inflammation, Virology, Neurology, Ophthalmology and Gastrointestinal diseases.  In addition to his work in the biotechnology and pharmaceutical industries, Dr. Parsey was the Director of Critical Care Medicine at the NYU School of Medicine.  He completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

"3-V has the opportunity, via the modulation of host-factor targets, to fundamentally change anti-viral treatment, and the company's founders, employees, and investors have created an environment to achieve this goal," said Dr. Parsey.  "I am excited to join the 3-V team and help turn this exciting science into therapies that have the potential to improve the lives of patients."

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationStephen R. BradyVice President, Corporate Development, Strategy & Operations650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Martek Biosciences Announces Agreement to Sell Majority of Winchester, Ky. Manufacturing Site
2. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
3. Ardea Biosciences to Present at Four Upcoming Investor Conferences
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen Universitys School of Pharmaceutical Sciences
6. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
8. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
9. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
10. Signum Biosciences, Inc. Announces Commercial Launch of Arazineā„¢
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):